Difference between revisions of "Rosai-Dorfman-Destombes disease"
Jump to navigation
Jump to search
m |
|||
| Line 15: | Line 15: | ||
==Consensus guidelines== | ==Consensus guidelines== | ||
*'''2018:''' Abla et al. [http://www.bloodjournal.org/content/131/26/2877.long Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease] [https://www.ncbi.nlm.nih.gov/pubmed/29720485 PubMed] | *'''2018:''' Abla et al. [http://www.bloodjournal.org/content/131/26/2877.long Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease] [https://www.ncbi.nlm.nih.gov/pubmed/29720485 PubMed] | ||
| + | |||
| + | =All lines of therapy= | ||
| + | ==Cobimetinib monotherapy {{#subobject:a6f6dd|Regimen=1}}== | ||
| + | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
| + | |- | ||
| + | |[[#top|back to top]] | ||
| + | |} | ||
| + | ===Regimen {{#subobject:#fecb7f|Variant=1}}=== | ||
| + | {| class="wikitable" style="width: 50%; text-align:center;" | ||
| + | !style="width: 25%"|Study | ||
| + | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
| + | |- | ||
| + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438729/ Diamond et al. 2019 (MSK 15-216)] | ||
| + | |style="background-color:#ffffbe"|Pilot, <20 pts in this arm | ||
| + | |- | ||
| + | |} | ||
| + | ''Note: there were N=2 patients with this type of histiocytosis.'' | ||
| + | ====Chemotherapy==== | ||
| + | *[[Cobimetinib (Cotellic)]] 60 mg PO once per day on days 1 to 21 | ||
| + | |||
| + | '''28-day cycles''' | ||
| + | ===References=== | ||
| + | # '''MSK 15-216:''' Diamond EL, Durham BH, Ulaner GA, Drill E, Buthorn J, Ki M, Bitner L, Cho H, Young RJ, Francis JH, Rampal R, Lacouture M, Brody LA, Ozkaya N, Dogan A, Rosen N, Iasonos A, Abdel-Wahab O, Hyman DM. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019 Mar;567(7749):521-524. Epub 2019 Mar 13. [https://www.nature.com/articles/s41586-019-1012-y link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438729/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/30867592 PubMed] | ||
[[Category:Rosai-Dorfman-Destombes disease regimens]] | [[Category:Rosai-Dorfman-Destombes disease regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Histiocytoses]] | [[Category:Histiocytoses]] | ||
Revision as of 16:23, 15 May 2019
| Section editor | |
|---|---|
 |
Ronald S. Go, MD Mayo Clinic Rochester, MN |
1 regimens on this page
1 variants on this page
|
Guidelines
Consensus guidelines
- 2018: Abla et al. Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease PubMed
All lines of therapy
Cobimetinib monotherapy
| back to top |
Regimen
| Study | Evidence |
|---|---|
| Diamond et al. 2019 (MSK 15-216) | Pilot, <20 pts in this arm |
Note: there were N=2 patients with this type of histiocytosis.
Chemotherapy
- Cobimetinib (Cotellic) 60 mg PO once per day on days 1 to 21
28-day cycles
References
- MSK 15-216: Diamond EL, Durham BH, Ulaner GA, Drill E, Buthorn J, Ki M, Bitner L, Cho H, Young RJ, Francis JH, Rampal R, Lacouture M, Brody LA, Ozkaya N, Dogan A, Rosen N, Iasonos A, Abdel-Wahab O, Hyman DM. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019 Mar;567(7749):521-524. Epub 2019 Mar 13. link to original article contains verified protocol link to PMC article PubMed